CoChat
Sign Up
Cited by 169

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Huntington's disease progression

Andrews, Thomasin C., Weeks, Robert A., Turjanski, Nora, Gunn, Roger N., Watkins, Laura H. A., Sahakian, Barbara, Hodges, John R., Rosser, Anne E., Wood, Nicholas W., Brooks, David J.·1999·Brain
DOI 10.1093/brain/122.12.2353
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/122.12.2353

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Our findings confirm the role of astrocytes as important regulatory cell types in brain function and behavior and in neurodegenerative disorders, including HD.

    “In conclusion, our findings confirm the role of astrocytes as important regulatory cell types in brain function and behavior 40,57 and in neurodegenerative disorders, including HD 58,59 .”

    From SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington’s disease phenotypes (2021) · cites this paper as [59]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 41

  1. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci1989; 12: 366–75. · DOI · Paper page
  2. Antonini A, Leenders KL. Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [11C]-raclopride. Ann N Y Acad Sci1993; 695: 81–5. · DOI
  3. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain1996; 119: 2085–95. · DOI
  4. Antonini A, Leenders KL, Eidelberg D. [11C]Raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol1998; 43: 253–5. · DOI
  5. Augood SJ, Faull RL, Emson PC. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol1997; 42: 215–21. · DOI
  6. Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology1994; 44: 823–8. · DOI
  7. Brandt J, Folstein SE, Wong DF, Links J, Dannals RF, McDonnell-Sill A, et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. J Neuropsychiatry Clin Neurosci1990; 2: 20–7. · DOI
  8. Chesselet MF, Delfs JM. Basal ganglia and movement disorders: an update [see comments]. [Review]. Trends Neurosci1996; 19: 417–22. Comment in: Trends Neurosci 1997; 20: 152–3. · DOI
  9. Davis MB, Bateman D, Quinn NP, Marsden CD, Harding AE. Mutation analysis in patients with possible but apparently sporadic Huntington's disease. Lancet1994; 344: 714–7. · DOI
  10. Ferrante RJ, Beal MF, Kowall NW, Richardson EP Jr, Martin JB. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res1987; 411: 162–6. · DOI
  11. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. [Review]. Trends Neurosci1997; 20: 482–7. · DOI
  12. Furtado S, Suchowersky O, Rewcastle B, Graham L, Klimek ML, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol1996; 39: 132–6. · DOI
  13. Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain1997; 120: 503–14. · DOI
  14. Grafton ST, Mazziotta JC, Pahl JJ, St. George-Hyslop P, Haines JL, Gusella J, et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. Arch Neurol1992; 49: 1161–7. · DOI · Paper page
  15. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science1985; 227: 770–3. · DOI
  16. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage1997; 6: 279–87. · DOI
  17. Hagglund J, Aquilonius SM, Eckernas SA, Hartvig P, Lundquist H, Gullberg P, et al. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone. Acta Neurol Scand1987; 75: 87–94. · DOI
  18. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord1996; 11: 136–42. · DOI
  19. Joyce JN, Lexow N, Bird E, Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse1988; 2: 546–57. · DOI
  20. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage1996; 4: 153–8. · DOI
  21. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab1996; 16: 42–52. · DOI
  22. Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov Disord1986; 1: 69–77. · DOI
  23. Marshall FJ, Shoulson I. Clinical features and treatment of Huntington's disease. In: Watts RL and Koller WC, editors. Movement disorders: neurological principles and practice. New York: McGraw Hill; 1997. p. 491–502.
  24. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol1984; 15: 217–27. · DOI
  25. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry1998; 64: 314–9. · DOI
  26. Penney JB Jr, Young AB. Striatal inhomogeneities and basal ganglia function. [Review]. Mov Disord1986; 1: 3–15. · DOI
  27. Rappaport MS, Sealfon SC, Prikhozhan A, Huntley GW, Morrison JH. Heterogeneous distribution of D1, D2 and D5 receptor mRNAs in monkey striatum. Brain Res1993; 616: 242–50. · DOI
  28. Richfield EK, O'Brien CF, Eskin T, Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci Lett1991; 132: 121–6. · DOI
  29. Robb RA, Hanson DP. A software system for interactive and quantitative visualization of multidimensional biomedical images. Australas Phys Eng Sci Med1991; 14: 9–30.
  30. Rubinsztein DC, Leggo J, Chiano M, Dodge A, Norbury G, Rosser E, et al. Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci USA1997; 94: 3872–6. · DOI
  31. Sedvall G, Karlsson P, Lundin A, Anvret M, Suhara T, Halldin C, et al. Dopamine D1 receptor number—a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatry Clin Neurosci1994; 243: 249–55. · DOI
  32. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA. Unified Huntington's Disease Rating Scale: a follow up. Move Disord1998; 13: 915–9. · DOI
  33. Simpson SA, Harding AE. Predictive testing for Huntington's disease: after the gene. The United Kingdom Huntington's Disease Prediction Consortium. J Med Genet1993; 30: 1036–8. · DOI
  34. Spinks TJ, Jones T, Gilardi MC, Heather JD. Physical performance of the latest generation of commercial positron scanner. IEEE Trans Nucl Sci1988; 35: 721–5. · DOI
  35. Spinks TJ, Jones T, Bailey DL, Townsend DW, Grootoonk S, Bloomfield PM, et al. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys Med Biol1992; 37: 1637–55. · DOI
  36. Studholme C, Hill DL, Hawkes DJ. Automated three-dimensional registration of magnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys1997; 24: 25–35. · DOI
  37. Surmeier DJ, Reiner A, Levine MS, Ariano MA. Are neostriatal dopamine receptors co-localized? [see comments]. [Review]. Trends Neurosci1993; 16: 299–305. Comment in: Trends Neurosci 1994; 17: 2–5. · DOI
  38. Torres EM, Fricker RA, Hume SP, Myers R, Opacka-Juffry J, Ashworth S, et al. Assessment of striatal graft viability in the rat in vivo using a small diameter PET scanner. Neuroreport1995; 6: 2017–21. · DOI
  39. Turjanski N, Weeks R, Dolan R, Harding AE, Brooks DJ. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain1995; 118: 689–96. · DOI
  40. Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R, et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain [published erratum appears in J Nucl Med 1993; 34: 838]. J Nucl Med1993; 34: 609–13.
  41. Weeks RA, Piccini P, Harding AE, Brooks DJ. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol1996; 40: 49–54. · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Andrews, T. C., Weeks, R. A., Turjanski, N., Gunn, R. N., Watkins, L. H. A., Sahakian, B., Hodges, J. R., Rosser, A. E., Wood, N. W., & Brooks, D. J.
Venue
Brain
Publisher
Oxford University Press (OUP)
Published
1999-12
Volume
122
Issue
12
Pages
2353-2363
ISSN
  • 1460-2156
  • 0006-8950
DOI
10.1093/brain/122.12.2353
Cited by
169
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review